Equities Analysts Set Expectations for Oculis Q1 Earnings

Oculis Holding AG (NASDAQ:OCS) – HC Wainwright lifted their Q1 2025 earnings estimates for Oculis in a report issued on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.43) per share for the quarter, up from their previous estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $29.00 target price on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

Several other equities research analysts have also recently weighed in on OCS. Robert W. Baird boosted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 target price on shares of Oculis in a report on Thursday, March 13th.

Oculis Price Performance

Oculis stock opened at $18.83 on Monday. The stock has a market cap of $822.16 million, a P/E ratio of -9.76 and a beta of 0.01. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $20.94 and a 200-day simple moving average of $17.05. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Institutional Trading of Oculis

Several hedge funds have recently modified their holdings of OCS. abrdn plc lifted its stake in shares of Oculis by 23.0% in the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after purchasing an additional 188,871 shares during the period. Bank of America Corp DE increased its holdings in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after buying an additional 10,667 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Oculis during the 4th quarter valued at approximately $389,000. Bellevue Group AG purchased a new stake in shares of Oculis during the 4th quarter worth approximately $170,000. Finally, Geode Capital Management LLC grew its holdings in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares during the period. 22.30% of the stock is owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.